The global liposome drug delivery market is projected to grow from US$5.9 billion in 2024 to US$29.6 billion by 2034, at a compound annual growth rate (CAGR) of 8.9%. This growth is driven by chronic disease burdens, technological advancements in liposome design, regulatory support from agencies like the FDA and EMA, and increasing adoption in cancer therapy, regenerative medicine, and gene therapy. Key product types include liposomal doxorubicin (41.3% market share), liposomal amphotericin B, and liposomal paclitaxel. Stealth liposome technology holds the largest market share (53.5%) due to its ability to extend drug circulation and target specific tissues. Cancer therapy accounts for 49.4% of market revenue, with hospitals being the leading end-users (52.5% share). North America leads the market with a 39.9% revenue share, while the Asia Pacific region is projected to grow at the fastest CAGR. Major players such as Gilead Sciences are investing in new liposomal therapies, and innovations like targeted delivery, smart liposomes, and combination therapies are enhancing treatment precision, safety, and efficacy.

The article discusses the analysis of levelised cost of electricity (LCOE) targets for small modular reactors (SMRs), highlighting the need for competitive pricing to make them viable for baseload power. It features insights from Lars Thurmann-Moe of Arthur D. Little, who emphasizes the role of SMRs in addressing global energy demands while addressing challenges like cost overruns and supply chain coordination. The text also covers global developments in SMR technology, including projects in the UK, US, Canada, China, and Russia.

The sarcopenia market is projected to grow significantly by 2034, with a 2024 market size of ~USD 2,000 million. Key companies like TNF Pharmaceuticals, Lipocine, and Biophytis are developing therapies, including FDA Fast Track Designations for LPCN 1148 and MF-300. The market is segmented across the 7MM (US, EU4, UK, Japan) with varying prevalence rates and therapeutic pipelines.

The article discusses the expected growth of the sarcopenia market by 2034, highlighting key companies like TNF Pharmaceuticals, Lipocine, and Biophytis, along with FDA designations and market trends.

Lipocine Inc. (NASDAQ:LPCN) stock crossed below its 200-day moving average at $3.20, with a volume of 15,926 shares. Brokerages like HC Wainwright reiterated a 'buy' rating with a $8.00 price target, while Wall Street Zen initiated coverage with a 'hold' rating. The company reported a net loss of $0.35 EPS and $0.09M revenue for the quarter, below estimates. Geode Capital Management increased its stake in the biopharmaceutical company, and the firm's lead product, TLANDO, is an oral testosterone replacement therapy.